Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia

BackgroundMethotrexate (MTX) is the primary drug used in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, some patients exhibit delayed clearance of high-dose (HD) MTX, which induces severe nephrotoxicity, mucositis, hepatotoxicity, and neurotoxicity. We sought to identify rel...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Jung Yoon Choi, Hoshik Kwon, Hyery Kim, Kyung Taek Hong, Youngeun Ma, Kyung-Nam Koh, Sunmin Yun, Keon Hee Yoo, Sang Hoon Song, Ho Joon Im, Ju Han Kim, Hyoung Jin Kang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Subjects:	methotrexate children acute lymphoblastic leukemia pediatric pharmacogenomics adverse reactions
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1480657/full